✦ LIBER ✦

Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial

✍ Scribed by Luigi Celio; Sergio Frustaci; Angela Denaro; Angela Buonadonna; Antonio Ardizzoia; Elena Piazza; Alessandra Fabi; Alba Maria Capobianco; Luciano Isa; Luigi Cavanna; Alessandro Bertolini; Ettore Bichisao; Emilio Bajetta; for the Italian Trials in Medical Oncology Group

Publisher: Springer-Verlag
Year: 2010
Tongue: English
Weight: 185 KB
Volume: 19
Category: Article
ISSN: 0941-4355
DOI: 10.1007/s00520-010-0941-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Improved prevention of moderately emetog

Improved prevention of moderately emetogenic chemotherapy-induced nausea and vomiting with palonosetron, a pharmacologically novel 5-HT3 receptor antagonist : Results of a Phase III, single-dose trial versus dolasetron

✍ Peter Eisenberg; Jazmin Figueroa-Vadillo; Rosalio Zamora; Veena Charu; Julio Haj 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 174 KB

## Background: Palonosetron, a highly selective and potent 5-ht(3) receptor antagonist with a strong binding affinity and a long plasma elimination half-life (approximately 40 hours), has shown efficacy in phase ii trials in preventing chemotherapy-induced nausea and vomiting (cinv) resulting from

Phase 2 trial results with the novel neu

Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy

✍ Wichit Arpornwirat; Istvan Albert; Vincent L. Hansen; Jeremey Levin; Rajesh R. B 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 172 KB 👁 1 views

Efficacy and tolerability of transdermal

Efficacy and tolerability of transdermal granisetron for the control of chemotherapy-induced nausea and vomiting associated with moderately and highly emetogenic multi-day chemotherapy: a randomized, double-blind, phase III study

✍ Ralph V. Boccia; Lucio N. Gordan; Gemma Clark; Julian D. Howell; Steven M. Grunb 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 185 KB

## Purpose A novel transdermal formulation of granisetron (the granisetron transdermal delivery system (GTDS)) has been developed to deliver granisetron continuously over 7 days. This double-blind, phase III, non-inferiority study compared the efficacy and tolerability of the GTDS to daily oral gra